MHRA Announces Crucial Safety Update for Omacor/Teromeg
The Medicines and Healthcare Products Regulatory Agency (MHRA) has recently updated the safety information for omega-3-acid ethyl ester medicines, commonly prescribed for hypertriglyceridemia. This change is crucial for patients relying on these medications, typically known as Omacor and Teromeg 1000 mg capsules.
Understanding Hypertriglyceridemia and Its Treatment
Addressing High Triglyceride Levels
Hypertriglyceridemia is a condition characterized by elevated triglyceride levels in the blood, posing risks such as coronary heart disease and pancreatitis. Omega-3-acid ethyl ester medicines are a primary treatment option when dietary modifications alone prove insufficient.
The Newly Added Safety Concern: Atrial Fibrillation
Recognizing the Symptoms
The MHRA has included atrial fibrillation – a condition marked by an abnormally fast and irregular heartbeat – in the safety information for these medicines. Patients should be vigilant for symptoms like palpitations, dizziness, shortness of breath, and fatigue, all potential indicators of atrial fibrillation.
Guidance for Patients: Do Not Halt Treatment Abruptly
Consult Healthcare Professionals First
Patients are advised not to discontinue their hypertriglyceridemia treatment without consulting their doctor. It’s imperative to inform healthcare providers about any current or past heart issues before using these medications.
For Healthcare Professionals: Monitoring and Decision-Making
Addressing Atrial Fibrillation
Healthcare experts should discontinue treatment with these medicines if a patient develops atrial fibrillation. This decision should be based on clinical judgment, weighing the individual benefits and risks for the patient.
The European Review and MHRA’s Decision
Addressing Cardiovascular Risks
The European review highlighted a dose-dependent increased risk of atrial fibrillation in patients with cardiovascular diseases or risk factors treated with these medicines. This finding led to the MHRA’s decision to update the product information, classifying atrial fibrillation as a common side effect.
Dr. Alison Cave’s Statement on Patient Safety
MHRA’s Commitment to Medication Safety
Dr. Alison Cave, MHRA Chief Safety Officer, emphasized the agency’s continuous review of medicine safety, including omega-3-acid ethyl esters. She highlighted the importance of patients reporting any symptoms indicative of atrial fibrillation and consulting their doctors before making any changes to their medication regimen.
Additional Important Facts
Understanding Atrial Fibrillation
Atrial fibrillation, characterized by a fast, irregularly irregular heart rate, can lead to complications like stroke if not addressed. As of 15 January 2024, the MHRA hasn’t received any reports linking atrial fibrillation with omega-3-acid ethyl ester medicinal products.
Parenteral Infusion Products
Several parenteral infusion products containing omega-3 acid triglycerides or omega-3 fish oil are available in the UK. Currently, atrial fibrillation is not listed as an adverse reaction for these products, and they remain unaffected by this regulatory action.
The Role of Omega-3
Omega-3 is essential for physiological development, especially for heart and nervous system health. It helps lower LDL cholesterol levels and is available in various forms, including natural triglycerides and ethyl esters.
MHRA’s Role and Responsibility
The MHRA, an executive agency of the Department of Health and Social Care, ensures that medicines and medical devices in the UK are effective and safe. However, it does not regulate food or dietary supplements marketed without medicinal claims.
Sources: THX News & Medicines and Healthcare products Regulatory Agency.
